Read the policies, reports, and plans on how we address issues like racism and reduce our carbon footprint, ensuring our actions align with the highest ethical standards.
In more than 70 countries, Médecins Sans Frontières provides medical humanitarian assistance to save lives and ease the suffering of people in crisis situations.
We set up the MSF Access Campaign in 1999 to push for access to, and the development of, life-saving and life-prolonging medicines, diagnostic tests and vaccines for people in our programmes and beyond.
Based in Paris, CRASH conducts and directs studies and analysis of MSF actions. They participate in internal training sessions and assessment missions in the field.
Based in Geneva, UREPH (or Research Unit) aims to improve the way MSF projects are implemented in the field and to participate in critical thinking on humanitarian and medical action.
Based in Brussels, MSF Analysis intends to stimulate reflection and debate on humanitarian topics organised around the themes of migration, refugees, aid access, health policy and the environment in which aid operates.
This logistical and supply centre in Brussels provides storage of and delivers medical equipment, logistics and drugs for international purchases for MSF missions.
This supply and logistics centre in Bordeaux, France, provides warehousing and delivery of medical equipment, logistics and drugs for international purchases for MSF missions.
This logistical centre in Amsterdam purchases, tests, and stores equipment including vehicles, communications material, power supplies, water-processing facilities and nutritional supplements.
BRAMU specialises in neglected tropical diseases, such as dengue and Chagas, and other infectious diseases. This medical unit is based in Rio de Janeiro, Brazil.
Our medical guidelines are based on scientific data collected from MSF’s experiences, the World Health Organization (WHO), other renowned international medical institutions, and medical and scientific journals.
Providing epidemiological expertise to underpin our operations, conducting research and training to support our goal of providing medical aid in areas where people are affected by conflict, epidemics, disasters, or excluded from health care.
Evaluation Units have been established in Vienna, Stockholm, and Paris, assessing the potential and limitations of medical humanitarian action, thereby enhancing the effectiveness of our medical humanitarian work.
MSF works with LGBTQI+ populations in many settings over the last 25-30 years. LGBTQI+ people face healthcare disparities with limited access to care and higher disease rates than the general population.
The Luxembourg Operational Research (LuxOR) unit coordinates field research projects and operational research training, and provides support for documentation activities and routine data collection.
The MSF Paediatric Days is an event for paediatric field staff, policy makers and academia to exchange ideas, align efforts, inspire and share frontline research to advance urgent paediatric issues of direct concern for the humanitarian field.
The MSF Foundation aims to create a fertile arena for logistics and medical knowledge-sharing to meet the needs of MSF and the humanitarian sector as a whole.
A collaborative, patients’ needs-driven, non-profit drug research and development organisation that is developing new treatments for neglected diseases, founded in 2003 by seven organisations from around the world.
Noma is a preventable and treatable neglected disease, but 90 per cent of people will die within the first two weeks of infection if they do not receive treatment.
Unaffordable, unavailable, not adapted - people around the world face these challenges in accessing lifesaving medicines.
During the 1990s, MSF teams made a bitter observation: we were failing to treat some of our patients suffering from infectious diseases, while in developed countries, remarkable progress was being made in the field of health. Two decades on, medicines in developing countries are still either too expensive, aren't suitable to be used in many of the contexts in which we work (for example, in hot, humid conditions or where there's a lack of electricity), or simply don't exist for the diseases we need to treat.
In 1999, we launched the Campaign for Access to Essential Medicines, now known as the Access Campaign. Its mission focuses on three areas: overcoming barriers to access to essential medicines, stimulating research and development for neglected diseases, promoting health exceptions to global trade agreements.
In 2003, MSF joined several research institutes, including the Institut Pasteur, to create the Drugs for Neglected Diseases initiative (DNDi), a non-profit research and development organisation engaged in research and development of new treatments for neglected diseases.
Residents deprived of critical medications and medical care
Project Update17 Nov 2011
Ethiopia
Surge in the number of Somali refugees demands increased capacity
Press Release2 Nov 2011
Access to medicines
Five Lives: How a Financial Transaction Tax Could Support Global Health
Report20 Oct 2011
Access to medicines
Proposed EU financial transaction tax should help bail out global health
Press Release20 Oct 2011
Chagas disease
Shortage of benznidazole leaves Chagas patients without treatment
Press Release5 Oct 2011
Libya
Providing urgent medical care in Sirte
Project Update4 Oct 2011
Tuberculosis
Towards Lab-Free Tuberculosis Diagnosis
Report22 Aug 2011
South Sudan
In Aweil hospital, South Sudan, focused on the most at risk
Project Update4 Aug 2011
HIV/AIDS
Gilead licence expands access, but several countries left out
Press Release12 Jul 2011
Related topics
Medical activities
HIV/AIDS
Around 630,000 people died from HIV-related causes, while 1.3 million people became newly infected with the HIV virus in 2022.
Medical activities
Hepatitis C
Worldwide, an estimated 58 million people are infected with the hepatitis C virus, with about 1.5 million new infections occurring per year. While hepatitis C can be cured, few people have access to treatment.
Medical activities
Tuberculosis
Tuberculosis (TB) is one of the world’s biggest global health crises. Killing 1.3 million people in 2022 TB is the world’s second deadliest infectious disease after COVID-19 (WHO).
